Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 May;88(2):360–366. doi: 10.1111/j.1365-2249.1992.tb03088.x

Relationship between a novel human cytotoxin (factor 2) produced by a B cell line (Karpas 160) and phorbol-myristate-acetate-associated cytotoxicity.

J Ni 1, A Karpas 1
PMCID: PMC1554294  PMID: 1572102

Abstract

We found that 160b cells, a subclone of Karpas 160 human B cell line, spontaneously secreted a novel cytotoxin, factor 2 (F2). F2 was also extracted from the cells by 60% ammonium sulphate, 0.5% CHAPS and 0.28% Triton X-114. We were able to show that phorbol myristate acetate (PMA) greatly enhanced the production of F2, and PMA may also account for part of the putative F2 cytotoxic activity to K562 cells in crude preparations. We compared the cytotoxic effect of F2 with PMA-associated F2-like cytotoxicity to K562 cells as well as the adequacy of our schemes to purified F2 with regard to its separation from PMA. We found that it was possible to separate PMA from F2 preparations by gel filtration and Rotofor preparative isoelectric focusing. The fate of PMA was also monitored with 3H-PMA and chromatographic profiles of 3H-PMA were studied using DE52 and gel filtration chromatography. We were able to establish that less than 2.9% of the cytotoxicity to K562 was due to PMA. We also found that the radioactive peaks and cytotoxicity peaks to K562 were not well correlated, indicating that the cytotoxicity was not mainly due to remaining PMA. Activated charcoal removed virtually all F2 and PMA but not tumour necrosis factor activity. Our results also showed that cytotoxicity to K562 resulting from F2 or PMA-associated proteins had different physicochemical properties, indicating that they are different molecular entities. These findings are consistent with the earlier observation that 160 cells produce F2 spontaneously and that PMA can amplify its production significantly.

Full text

PDF
360

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggarwal B. B., Henzel W. J., Moffat B., Kohr W. J., Harkins R. N. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem. 1985 Feb 25;260(4):2334–2344. [PubMed] [Google Scholar]
  2. Aggarwal B. B. Human lymphotoxin. Methods Enzymol. 1985;116:441–448. doi: 10.1016/s0076-6879(85)16035-0. [DOI] [PubMed] [Google Scholar]
  3. Aggarwal B. B., Kohr W. J., Hass P. E., Moffat B., Spencer S. A., Henzel W. J., Bringman T. S., Nedwin G. E., Goeddel D. V., Harkins R. N. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem. 1985 Feb 25;260(4):2345–2354. [PubMed] [Google Scholar]
  4. Aggarwal B. B., Moffat B., Harkins R. N. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem. 1984 Jan 10;259(1):686–691. [PubMed] [Google Scholar]
  5. Blumberg P. M. In vitro studies on the mode of action of the phorbol esters, potent tumor promoters, part 2. Crit Rev Toxicol. 1981 Jun;8(3):199–234. doi: 10.3109/10408448109109658. [DOI] [PubMed] [Google Scholar]
  6. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem. 1981 Feb 25;256(4):1604–1607. [PubMed] [Google Scholar]
  7. Béchet J. M., Guétard D. Differential cytotoxicity of tumour promoter TPA for EBV-negative human lymphoma cell lines and their EBV-converted sublines. Int J Cancer. 1983 Jul 15;32(1):61–65. doi: 10.1002/ijc.2910320110. [DOI] [PubMed] [Google Scholar]
  8. Dokhelar M. C., Garson D., Wakasugi H., Tabilio A., Testa U., Vainchenker W., Tursz T. K562 cells induced to differentiate by phorbol ester tumor promotors resist NK lysis. Cell Immunol. 1984 Sep;87(2):389–399. doi: 10.1016/0008-8749(84)90008-x. [DOI] [PubMed] [Google Scholar]
  9. Dukovich M., Mizel S. B. Murine interleukin 1. Methods Enzymol. 1985;116:480–492. doi: 10.1016/s0076-6879(85)16039-8. [DOI] [PubMed] [Google Scholar]
  10. Fukuda S., Ando S., Sanou O., Taniai M., Fujii M., Masaki N., Nakamura K., Ando O., Torigoe K., Sugimoto T. Simultaneous production of natural human tumor necrosis factor-alpha, -beta and interferon-alpha from BALL-1 cells stimulated by HVJ. Lymphokine Res. 1988 Summer;7(2):175–185. [PubMed] [Google Scholar]
  11. Green L. M., Reade J. L., Ware C. F. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods. 1984 May 25;70(2):257–268. doi: 10.1016/0022-1759(84)90190-x. [DOI] [PubMed] [Google Scholar]
  12. Karpas A. A human haemic cell line capable of cellular and humoral killing of normal and malignant cells. Br J Cancer. 1977 Feb;35(2):152–160. doi: 10.1038/bjc.1977.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Karpas A. A humoral cytotoxic substance produced by a human killer cell line. Br J Cancer. 1977 Oct;36(4):437–445. doi: 10.1038/bjc.1977.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Karpas A. Human B-cell cytotoxic lymphokine priority. Nature. 1985 Feb 21;313(6004):636–636. doi: 10.1038/313636b0. [DOI] [PubMed] [Google Scholar]
  15. Krakauer T., Mizel D., Oppenheim J. J. Independent and synergistic thymocyte proliferative activities of PMA and IL 1. J Immunol. 1982 Sep;129(3):939–941. [PubMed] [Google Scholar]
  16. Little J. B., Nagasawa H., Weichselbaum R. R., Lovett D. R., Schmit A., Kochenburger R. J., Blumberg P. M. Differing patterns of cytotoxicity of the phorbol ester 12-O-tetradecanoylphorbol 13-acetate in various human cell strains. Carcinogenesis. 1985 Dec;6(12):1703–1708. doi: 10.1093/carcin/6.12.1703. [DOI] [PubMed] [Google Scholar]
  17. Ortaldo J. R., Ransom J. R., Sayers T. J., Herberman R. B. Analysis of cytostatic/cytotoxic lymphokines: relationship of natural killer cytotoxic factor to recombinant lymphotoxin, recombinant tumor necrosis factor, and leukoregulin. J Immunol. 1986 Nov 1;137(9):2857–2863. [PubMed] [Google Scholar]
  18. Ortaldo J. R., Winkler-Pickett R., Morgan A. C., Woodhouse C., Kantor R., Reynolds C. W. Analysis of rat natural killer cytotoxic factor (NKCF) produced by rat NK cell lines and the production of a murine monoclonal antibody that neutralizes NKCF. J Immunol. 1987 Nov 1;139(9):3159–3165. [PubMed] [Google Scholar]
  19. Sayers T. J., Ransom J. H., Denn A. C., 3rd, Herberman R. B., Ortaldo J. R. Analysis of a cytostatic lymphokine produced by incubation of lymphocytes with tumor cells: relationship to leukoregulin and distinction from recombinant lymphotoxin, recombinant tumor necrosis factor, and natural killer cytotoxic factor. J Immunol. 1986 Jul 1;137(1):385–390. [PubMed] [Google Scholar]
  20. Williams L. D., McMaster W. R., Teh H. S. Antigen-independent activation of cytotoxic T cells by lymphokines. Immunology. 1988 May;64(1):121–128. [PMC free article] [PubMed] [Google Scholar]
  21. Yamanaka H. I., Karpas A. Identity of human B-cell line cytotoxic lymphokine with tumor necrosis factor type beta. Proc Natl Acad Sci U S A. 1989 Feb;86(4):1343–1347. doi: 10.1073/pnas.86.4.1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Zanyk M. J., Banerjee D., McFarlane D. L. Transferrin receptor and 4F2 expression by NK-sensitive and NK-resistant tumour cell lines. Carcinogenesis. 1988 Aug;9(8):1377–1381. doi: 10.1093/carcin/9.8.1377. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES